The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.
Get full access to this article
View all access options for this article.
References
1.
National Comprehensive Cancer Network.NCCN Clinical Practice Guidelines in Oncology - breast cancer. v.2.2010.http://www.nccn.org/. Accessed October 19, 2010.
2.
Avastin [product information].South San Francisco, CA: Genentech, Inc; 2009.
3.
MillerK., WangM., GralowJ.. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med.2007; 357(26): 2666–2676.
4.
ArdavanisA., DoufexisD., KountourakisP.. Salvage therapy of pretreated advanced breast cancer with bevacizumab and paclitaxel every two weeks: a retrospective case review study. BMC Cancer.2009; 9: 338.
5.
PolyzosA., KalbakisK., GiassasS.. Salvage treatment in metastatic breast cancer with weekly paclitaxel plus biweekly bevacizumab. J Clin Oncol.2010; 28(15 suppl): e11503.
6.
BrufskyA., HoelzerK., KeatonM.. A phase II study of paclitaxel and bevacizumab ± gemcitabine as first-line treatment for metastatic breast cancer: interim safety results. J Clin Oncol.2008; 26(15 suppl): 1095.
7.
HoelzerK.L., BrufskyA., HainsworthJ.. Preliminary results of a randomized phase II study of paclitaxel and bevacizumab ± gemcitabine as first-line treatment for metastatic breast cancer. J Clin Oncol.2009; 27(15 suppl):1089.
8.
MayerE.L., DhakilS., PatelT.. SABRE-B: an evaluation of paclitaxel and bevacizumab with or without sunitinib as first-line treatment of metastatic breast cancer. Ann Oncol. May 23, 2010. [Epub ahead of print].
9.
LangI., InbarM., GreilR.. Bevacizumab combined with either capecitabine or weekly paclitaxel as first-line chemotherapy for HER2-negative, locally recurrent or metastatic breast cancer: preliminary safety data from the CECOG phase III TURANDOT trial. J Clin Oncol.2010; 28(15 suppl):1126.
10.
MasudaN., AogiK., OhnoH.. Phase II study of bevacizumab combined with weekly paclitaxel as first-line therapy for Japanese patients with HER2-negative metastatic breast cancer. J Clin Oncol.2010; 28(15 suppl):1121.
11.
HurtJ., RichardsonD., SeamonL.. Sustained progression-free survival with weekly paclitaxel and bevacizumab in recurrent ovarian cancer. Gynecol Oncol.2009; 115(3): 396–400.
12.
Gonzalez-CaoM., ViteriS., LagaresA.. Preliminary results of the combination of bevacizumab and weekly paclitaxel in advanced melanoma. Oncology.2008; 74(1): 12–16.
13.
JalalS., BhatiaS., EinhornL.. Paclitaxel plus bevacizumab in patients with chemosensitive relapsed small cell lung cancer: a safety, feasibility and efficacy trial from the Hoosier Oncology Group. J Clin Oncol.2008; 26(15 suppl): 19013.
14.
National Comprehensive Cancer Network.NCCN Clinical Practice Guidelines - antiemesis. v.2.2010. http://www.nccn.org. Accessed August 19, 2010.
15.
Kris MG, Hesketh PJ, Somerfield MR, et al.American Society of Clinical Oncology Guideline for Antiemetics in Oncology: update 2006. J Clin Oncol.2006; 24(18): 2932–2947.
16.
Multinational Association of Supportive Care in Cancer antiemetic guidelines.www.mascc.org. Multinational Association of Supportive Care in Cancer Web site. Published March 2008. Accessed August 19, 2010.
National Comprehensive Cancer Network.NCCN Clinical Practice Guidelines in Oncology - myeloid growth factors. v.1.2010. http://www.nccn.org. Accessed August 19, 2010.
19.
KintzelP.E., DorrR.T.Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat Rev.1995; 21: 33–64.
